Mycophenolic acid

Last updated
Mycophenolic acid
Mycophenolicacid.svg
Mycophenolic acid ball-and-stick.png
Clinical data
Pronunciation /ˌmaɪkoʊfɪˈnɒlɪk/
Trade names Cellcept, Myfortic, others
Other namesMPA, Mycophenolate sodium, Mycophenolate mofetil (AAN AU), Mycophenolate mofetil (USAN US)
AHFS/Drugs.com Monograph
MedlinePlus a601081
License data
Pregnancy
category
Routes of
administration 		By mouth, intravenous [2]
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 72% (sodium),
94% (mofetil) [10]
Protein binding 82–97% [10]
Metabolism Liver [10]
Elimination half-life 17.9±6.5 hours [10]
Excretion Urine (93%),
faeces (6%) [10]
Identifiers
  • (4E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.041.912 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C17H20O6
Molar mass 320.341 g·mol−1
3D model (JSmol)
  • O=C1OCc2c1c(O)c(c(OC)c2C)C\C=C(/C)CCC(=O)O
  • InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+ Yes check.svgY
  • Key:HPNSFSBZBAHARI-RUDMXATFSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Mycophenolic acid is an immunosuppressant medication used to prevent rejection following organ transplantation and to treat autoimmune conditions such as Crohn's disease and lupus. [11] [12] Specifically it is used following kidney, heart, and liver transplantation. [12] It can be given by mouth or by injection into a vein. [12] It comes as mycophenolate sodium and mycophenolate mofetil. [12]

Contents

Common side effects include nausea, infections, and diarrhea. [12] Other serious side effects include an increased risk of cancer, progressive multifocal leukoencephalopathy, anemia, and gastrointestinal bleeding. [12] Use during pregnancy may harm the baby. [12] It works by blocking inosine monophosphate dehydrogenase (IMPDH), which is needed by lymphocytes to make guanosine. [12]

Mycophenolic acid was initially discovered by Italian Bartolomeo Gosio in 1893. [13] [14] It was rediscovered in 1945 and 1968. [14] It was approved for medical use in the United States in 1995 following the discovery of its immunosuppressive properties in the 1990s. [12] [13] It is available as a generic medication. [15] In 2020, it was the 313th most commonly prescribed medication in the United States, with more than 900 thousand prescriptions. [16]

Medical uses

Organ transplant

Mycophenolate is used for the prevention of organ transplant rejection. Mycophenolate mofetil is indicated for the prevention of organ transplant rejection in adults and kidney transplantation rejection in children over 2 years; whereas mycophenolate sodium is indicated for the prevention of kidney transplant rejection in adults. Mycophenolate sodium has also been used for the prevention of rejection in liver, heart, or lung transplants in children older than two years. [17]

Autoimmune disease

Mycophenolate is increasingly utilized as a steroid sparing treatment in autoimmune diseases and similar immune-mediated disorders including Behçet's disease, pemphigus vulgaris, immunoglobulin A nephropathy, small vessel vasculitides, and psoriasis. [18] It is also used for retroperitoneal fibrosis along with a number of other medications. [19] Specifically it has also be used for psoriasis not treatable by other methods. [20]

Its increasing application in treating lupus nephritis has demonstrated more frequent complete response and less frequent complications [18] compared to cyclophosphamide bolus therapy, a regimen with risk of bone marrow suppression, infertility, and malignancy. [11] Further work addressing maintenance therapy demonstrated mycophenolate superior to cyclophosphamide, again in terms of response and side-effects. [11] [21] Walsh proposed that mycophenolate should be considered as a first-line induction therapy for treatment of lupus nephritis in people without kidney dysfunction. [22]

Comparison to other agents

Compared with azathioprine it has higher incidence of diarrhea, and no difference in risk of any of the other side effects in transplant patients. [23] Mycophenolic acid is 15 times more expensive than azathioprine. [24]

Adverse effects

Common adverse drug reactions (≥ 1% of people) include diarrhea, nausea, vomiting, joint pain; infections, leukopenia, or anemia reflect the immunosuppressive and myelosuppressive nature of the drug. Mycophenolate sodium is also commonly associated with fatigue, headache, cough and/or breathing issues. Intravenous (IV) administration of mycophenolate mofetil is also commonly associated with thrombophlebitis and thrombosis. Infrequent adverse effects (0.1–1% of people) include esophagitis, gastritis, gastrointestinal tract hemorrhage, and/or invasive cytomegalovirus (CMV) infection. [17] More rarely, pulmonary fibrosis or various neoplasia occur: melanoma, lymphoma, other malignancies having an occurrences of 1 in 20 to 1 in 200, depending on the type, with neoplasia in the skin being the most common site. [25] [26] [ not specific enough to verify ] Several cases of pure red cell aplasia (PRCA) have also been reported. [27]

The U.S. Food and Drug Administration (FDA) issued an alert that people are at increased risk of opportunistic infections, such as activation of latent viral infections, including shingles, other herpes infections, cytomegalovirus, and BK virus associated nephropathy. In addition the FDA is investigating[ when? ] 16 people that developed a rare neurological disease while taking the drug. This is a viral infection known as progressive multifocal leukoencephalopathy; it attacks the brain and is usually fatal. [28]

Pregnancy

Mycophenolic acid is associated with miscarriage and congenital malformations when used during pregnancy, and should be avoided whenever possible by women trying to get pregnant. [29] [30]

Blood tests

Among the most common effects of this drug is increased blood cholesterol levels. Other changes in blood chemistry such as hypomagnesemia, hypocalcemia, hyperkalemia, and an increase in blood urea nitrogen (BUN) can occur. [2] [31]

Mechanism of action

Purines (including the nucleosides guanosine and adenosine) can either be synthesized de novo using ribose 5-phosphate or they can be salvaged from free nucleotides. Mycophenolic acid is a potent, reversible, non-competitive inhibitor of inosine-5′-monophosphate dehydrogenase (IMPDH), an enzyme essential to the de novo synthesis of guanosine-5'-monophosphate (GMP) from inosine-5'-monophosphate (IMP). [32] IMPDH inhibition particularly affects lymphocytes since they rely almost exclusively on de novo purine synthesis. [33] In contrast, many other cell types use both pathways, and some cells, such as terminally differentiated neurons, depend completely on purine nucleotide salvage. [34] Thus, use of mycophenolic acid leads to a relatively selective inhibition of DNA replication in T cells and B cells.

Pharmacology

Mycophenolate can be derived from the fungi Penicillium stoloniferum , P. brevicompactum and P. echinulatum . [35] Mycophenolate mofetil is metabolised in the liver to the active moiety mycophenolic acid. It reversibly inhibits inosine monophosphate dehydrogenase, [36] the enzyme that controls the rate of synthesis of guanine monophosphate in the de novo pathway of purine synthesis used in the proliferation of B and T lymphocytes. [37] Other cells recover purines via a separate salvage pathway and are thus able to escape the effect. [2]

Mycophenolate is potent and can, in many contexts, be used in place of the older anti-proliferative azathioprine. [38] It is usually used as part of a three-compound regimen of immunosuppressants, also including a calcineurin inhibitor (ciclosporin or tacrolimus) and a glucocorticoid (e.g. dexamethasone or prednisone). [39]

Chemistry

Mycophenolate mofetil, a prodrug form of mycophenolic acid used in medicine Mycophenolate mofetil structure.png
Mycophenolate mofetil, a prodrug form of mycophenolic acid used in medicine

Mycophenolate mofetil is the morpholino ‌ ethyl ester of mycophenolic acid; the ester masks the carboxyl group. [40] Mycophenolate mofetil is reported to have a pKa values of 5.6 for the morpholino moiety and 8.5 for the phenolic group.

History

Mycophenolic acid was discovered by Italian medical scientist Bartolomeo Gosio. Gosio collected a fungus from spoiled corn and named it Penicillium glaucum. (The species is now called P. brevicompactum .[ citation needed ]) In 1893 he found that the fungus had antibacterial activity. In 1896 he isolated crystals of the compound, which he successfully demonstrated as the active antibacterial compound against the anthrax bacterium. [20] This was the first antibiotic that was isolated in pure and crystalline form. But the discovery was forgotten. [41] It was rediscovered by two American scientists C.L. Alsberg and O.M. Black in 1912, and given the name mycophenolic acid. The compound was eventually demonstrated to have antiviral, antifungal, antibacterial, anticancer, and antipsoriasis activities. [42] Although it is not commercialised as antibiotic due to its adverse effects, its modified compound (ester derivative) is an approved immunosuppressant drug in kidney, heart, and liver transplantations, and is marketed under the brands CellCept (mycophenolate mofetil by Roche) and Myfortic (mycophenolate sodium by Novartis). [43]

Cellcept was developed by a South African geneticist Anthony Allison and his wife Elsie M. Eugui. In the 1970s while working at the Medical Research Council, Allison investigated the biochemical causes of immune deficiency in children. He discovered the metabolic pathway involving an enzyme, inosine monophosphate dehydrogenase, which is responsible for undesirable immune response in autoimmune diseases, as well as for immune rejection in organ transplantation. He conceived an idea that if a molecule that could block the enzyme is discovered, then, it would become an immunosuppressive drug that could be used for autoimmune diseases and in organ transplantation. In 1981 he decided to go for drug discovery and approached several pharmaceutical companies, which turned him down one by one as he had no primary knowledge of drug research. However, Syntex liked his plans and asked him to join the company with his wife. [44] He became vice president for the research. In one of their experiments the Allisons used an antibacterial compound, mycophenolate mofetil, which was abandoned in clinical use due to its adverse effects. They discovered that the compound had immunosuppressive activity. [45] [46] They synthesised a chemical variant for increased activity and reduced adverse effects. [47] [48] [49] [50] [51] They subsequently demonstrated that it was useful in organ transplantation in experimental rats. [52] [53] After successful clinical trials, [54] the compound was approved for use in kidney transplant by the U.S. Food and Drug Administration on 3 May 1995, [55] and was sold under the brand name CellCept. [56] [57] It was approved for use in the European Union in February 1996. [9]

Names

It was initially introduced as the prodrug mycophenolate mofetil (MMF, trade name CellCept) to improve oral bioavailability. The salt mycophenolate sodium has also been introduced. Enteric-coated mycophenolate sodium (EC-MPS) is an alternative MPA formulation.

MMF and EC-MPS appear to be equal in benefits and safety. [58]

Research

Mycophenolate mofetil is beginning to be used in the management of auto-immune disorders such as idiopathic thrombocytopenic purpura (ITP), systemic lupus erythematosus (SLE), scleroderma (systemic sclerosis or SSc), and pemphigus vulgaris (PV) with success for some patients. [59]

It is also currently being used as a long-term therapy for maintaining remission of granulomatosis with polyangiitis, though thus far, studies have found it inferior to azathioprine.[ citation needed ] A combination of mycophenolate and ribavirin has been found to stop infection by and replication of dengue virus in vitro . [60] [61] It has also shown promising antiviral activity against MERS, especially in combination with interferon. [62]

Preliminary data suggests that mycophenolate mofetil might have benefits in people with multiple sclerosis. However the evidence is insufficient to determine the effects as an add‐on therapy for interferon beta-1a in people with RRMS. [63]

Related Research Articles

<span class="mw-page-title-main">Tacrolimus</span> Immunosuppressive drug

Tacrolimus, sold under the brand name Prograf among others, is an immunosuppressive drug. After allogenic organ transplant, the risk of organ rejection is moderate. To lower the risk of organ rejection, tacrolimus is given. The drug can also be sold as a topical medication in the treatment of T-cell-mediated diseases such as eczema and psoriasis. For example, it is prescribed for severe refractory uveitis after a bone marrow transplant, exacerbations of minimal change disease, Kimura's disease, and vitiligo. It can be used to treat dry eye syndrome in cats and dogs.

<span class="mw-page-title-main">Immunosuppression</span> Decreased resistance to infection

Immunosuppression is a reduction of the activation or efficacy of the immune system. Some portions of the immune system itself have immunosuppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.

<span class="mw-page-title-main">Immunosuppressive drug</span> Drug that inhibits activity of immune system

Immunosuppressive drugs, also known as immunosuppressive agents, immunosuppressants and antirejection medications, are drugs that inhibit or prevent the activity of the immune system.

<span class="mw-page-title-main">Pancreas transplantation</span>

A pancreas transplant is an organ transplant that involves implanting a healthy pancreas into a person who usually has diabetes.

<span class="mw-page-title-main">Azathioprine</span> Immunosuppressive medication

Azathioprine, sold under the brand name Imuran, among others, is an immunosuppressive medication. It is used for the treatment of rheumatoid arthritis, granulomatosis with polyangiitis, Crohn's disease, ulcerative colitis, and systemic lupus erythematosus; and in kidney transplants to prevent rejection. It is listed by the International Agency for Research on Cancer as a group 1 human carcinogen. It is taken by mouth or injected into a vein.

Basiliximab, sold under the brand name Simulect, is a monoclonal antibody used to prevent rejection in kidney transplants. It is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used in combination with other medicines used to prevent organ rejection.

<span class="mw-page-title-main">Leukopenia</span> Medical condition

Leukopenia is a decrease in the number of leukocytes (WBC). Found in the blood, they are the white blood cells, and are the body's primary defense against an infection. Thus the condition of leukopenia places individuals at increased risk of infection.

<span class="mw-page-title-main">Lupus nephritis</span> Inflammation of the kidneys

Lupus nephritis is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), an autoimmune disease. It is a type of glomerulonephritis in which the glomeruli become inflamed. Since it is a result of SLE, this type of glomerulonephritis is said to be secondary, and has a different pattern and outcome from conditions with a primary cause originating in the kidney. The diagnosis of lupus nephritis depends on blood tests, urinalysis, X-rays, ultrasound scans of the kidneys, and a kidney biopsy. On urinalysis, a nephritic picture is found and red blood cell casts, red blood cells and proteinuria is found.

<span class="mw-page-title-main">Cyclophosphamide</span> Medication used as chemotherapy and to suppress the immune system

Cyclophosphamide (CP), also known as cytophosphane among other names, is a medication used as chemotherapy and to suppress the immune system. As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma. As an immune suppressor it is used in nephrotic syndrome, granulomatosis with polyangiitis, and following organ transplant, among other conditions. It is taken by mouth or injection into a vein.

<span class="mw-page-title-main">BK virus</span> Member of the polyomavirus family

The BK virus, also known as Human polyomavirus 1, is a member of the polyomavirus family. Past infection with the BK virus is widespread, but significant consequences of infection are uncommon, with the exception of the immunocompromised and the immunosuppressed. BK virus is an abbreviation of the name of the first patient, from whom the virus was isolated in 1971.

Synergistic enhancers of antiretrovirals usually do not possess any antiretroviral properties alone, but when they are taken concurrently with antiretroviral drugs they enhance the effect of that drug.

Purine metabolism refers to the metabolic pathways to synthesize and break down purines that are present in many organisms.

<span class="mw-page-title-main">Inosine-5′-monophosphate dehydrogenase</span> Class of enzymes

Inosine-5′-monophosphate dehydrogenase (IMPDH) is a purine biosynthetic enzyme that catalyzes the nicotinamide adenine dinucleotide (NAD+)-dependent oxidation of inosine monophosphate (IMP) to xanthosine monophosphate (XMP), the first committed and rate-limiting step towards the de novo biosynthesis of guanine nucleotides from IMP. IMPDH is a regulator of the intracellular guanine nucleotide pool, and is therefore important for DNA and RNA synthesis, signal transduction, energy transfer, glycoprotein synthesis, as well as other process that are involved in cellular proliferation.

<span class="mw-page-title-main">Mizoribine</span> Immunosuppressive drug

Mizoribine is an immunosuppressive drug. The compound was first observed in Tokyo, Japan, in 1971. First isolated from the fungus Penicillium brefeldianum. Mizoribine (MZB) is an imidazole nucleoside that has been used in renal transplantation, and in steroid-resistant nephrotic syndrome, IgA nephropathy, lupus, as well as for adults with rheumatoid arthritis, lupus nephritis and other rheumatic diseases. MZB exerts its activity through selective inhibition of inosine monophosphate dehydrogenase and guanosine monophosphate synthetase, resulting in the complete inhibition of guanine nucleotide synthesis without incorporation into nucleotides. It arrests DNA synthesis in the S phase of cellular division. Thus, MZB has less toxicity than azathioprine, another immunosuppressant used for some of the same diseases.

Diffuse proliferative glomerulonephritis (DPGN) is a type of glomerulonephritis that is the most serious form of renal lesions in SLE and is also the most common, occurring in 35% to 60% of patients. In absence of SLE, DPGN pathology looks more like Membranoproliferative glomerulonephritis

<span class="mw-page-title-main">IMPDH2</span> Protein-coding gene in the species Homo sapiens

Inosine-5'-monophosphate dehydrogenase 2, also known as IMP dehydrogenase 2, is an enzyme that in humans is encoded by the IMPDH2 gene.

<span class="mw-page-title-main">Voclosporin</span> Chemical compound

Voclosporin, sold under the brand name Lupkynis, is a calcineurin inhibitor used as an immunosuppressant medication for the treatment of lupus nephritis. It is an analog of ciclosporin that has enhanced action against calcineurin and greater metabolic stability.

The enzyme mycophenolic acid acyl-glucuronide esterase (EC 3.1.1.93, mycophenolic acid acyl-glucuronide deglucuronidase; AcMPAG deglucuronidase; systematic name mycophenolic acid O-acyl-glucuronide-ester hydrolase), is in humans encoded by the ABHD10 gene, and catalyses the reaction

Anthony Clifford Allison was a South African geneticist and medical scientist who made pioneering studies on the genetic resistance to malaria. Clark completed his primary schooling in Kenya, completed his higher education in South Africa, and obtained a BSc in medical science from the University of the Witwatersrand in 1947. He earned his PhD from the University of Oxford in 1950. After working at the Radcliffe Infirmary for two years, he worked as post-doctoral student to Linus Pauling in 1954. After teaching medicine for three years at Oxford, he worked at the Medical Research Council in London. In 1978 he simultaneously worked at the International Laboratory for Research on Animal Diseases (ILRAD) as its Director, and at the World Health Organization's (WHO) Immunology Laboratory, both in Nairobi. He later became the Vice President for Research at Syntex Corporation (1981-1994).

<span class="mw-page-title-main">Bartolomeo Gosio</span>

Bartolomeo Gosio was an Italian medical scientist. He discovered a toxic fume, eponymously named "Gosio gas", which is produced by microorganisms, that killed many people. He identified the chemical nature of the gas as an arsenic compound (arsine), but incorrectly named it as diethylarsine. He also discovered an antibacterial compound called mycophenolic acid from the mould Penicillium brevicompactum. He demonstrated that the novel compound was effective against the deadly anthrax bacterium, Bacillus anthracis. This was the first antibiotic compound isolated in pure and crystallised form. Though the original compound was abandoned in clinical practice due to its adverse effects, its chemical derivative mycophenolate mofetil became the drug of choice as an immunosuppressant in kidney, heart, and liver transplantations.

References

  1. ↑ "Mycophenolate mofetil (CellCept) Use During Pregnancy". Drugs.com. 24 January 2020. Archived from the original on 28 October 2019. Retrieved 6 April 2020.
  2. 1 2 3 Jasek W, ed. (2007). Austria-Codex (in German) (62nd ed.). Vienna: Österreichischer Apothekerverlag. pp. 1484–95. ISBN   978-3-85200-181-4.
  3. ↑ "CellCept® (mycophenolate mofetil)". Australian Product Information. 30 November 2021. Archived from the original on 2023-01-08. Retrieved 2023-01-08.
  4. ↑ "Pharmacor mycophenolate, mycocell, alcept (Pharmacor Pty Ltd)". Therapeutic Goods Administration (TGA). 11 November 2022. Archived from the original on 18 March 2023. Retrieved 29 April 2023.
  5. ↑ "CellCept 1g/5ml powder for oral suspension - Summary of Product Characteristics (SmPC)". (emc). 27 February 2020. Archived from the original on 25 September 2020. Retrieved 22 October 2020.
  6. ↑ "Cellcept 250mg Capsules - Summary of Product Characteristics (SmPC)". (emc). 17 June 2020. Archived from the original on 25 September 2020. Retrieved 22 October 2020.
  7. ↑ "Cellcept 500mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 25 September 2020. Retrieved 22 October 2020.
  8. ↑ "CellCept- mycophenolate mofetil tablet, film coated CellCept- mycophenolate mofetil capsule CellCept- mycophenolate mofetil hydrochloride injection, powder, lyophilized, for solution CellCept- mycophenolate mofetil powder, for suspension". DailyMed. Archived from the original on 24 October 2020. Retrieved 23 October 2020.
  9. 1 2 "CellCept EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 6 April 2020. Retrieved 6 April 2020.
  10. 1 2 3 4 5 "CellCept" (PDF). TGA eBusiness Services. Roche Products Pty Limited. 13 December 2012. Archived from the original on 8 July 2020. Retrieved 25 February 2014.
  11. 1 2 3 D'Cruz DP, Khamashta MA, Hughes GR (February 2007). "Systemic lupus erythematosus". Lancet. 369 (9561): 587–96. CiteSeerX   10.1.1.1008.5428 . doi:10.1016/S0140-6736(07)60279-7. PMID   17307106. S2CID   28468112.
  12. 1 2 3 4 5 6 7 8 9 "Mycophenolate Monograph for Professionals". Drugs.com. Archived from the original on 21 April 2020. Retrieved 28 October 2019.
  13. 1 2 Schiff ER, Maddrey WC, Sorrell MF (2011). Schiff's Diseases of the Liver. John Wiley & Sons. p. PT3219. ISBN   978-1-119-95048-6. Archived from the original on 2023-04-29. Retrieved 2020-09-23.
  14. 1 2 Laskin AI, Bennett JW, Gadd GM (2001). Advances in Applied Microbiology. Gulf Professional Publishing. p. 236. ISBN   978-0-12-002648-7. Archived from the original on 2023-04-29. Retrieved 2020-09-23.
  15. ↑ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 826–827. ISBN   978-0-85711-338-2.
  16. ↑ "Mycophenolate Mofetil - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 7 October 2022.
  17. 1 2 Rossi S, ed. (2006). Australian Medicines Handbook. Adelaide: Australian Medicines Handbook. ISBN   978-0-9757919-2-9.[ page needed ]
  18. 1 2 Moore RA, Derry S (2006). "Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis". Arthritis Research & Therapy. 8 (6): R182. doi: 10.1186/ar2093 . PMC   1794528 . PMID   17163990.
  19. ↑ Harber M (2014). Harber M (ed.). Practical nephrology. Springer. p. 449. ISBN   978-1-4471-5547-8. Archived from the original on 2023-04-29. Retrieved 2020-09-23.
  20. 1 2 Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL (September 1997). "Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses". Journal of the American Academy of Dermatology. 37 (3 Pt 1): 445–9. doi: 10.1016/S0190-9622(97)70147-6 . PMID   9308561.
  21. ↑ Singh JA, Hossain A, Kotb A, Wells GA (September 2016). "Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis". Systematic Reviews. 5 (1): 155. doi: 10.1186/s13643-016-0328-z . PMC   5020478 . PMID   27619512.
  22. ↑ Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR (September 2007). "Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis". Clinical Journal of the American Society of Nephrology. 2 (5): 968–75. doi: 10.2215/CJN.01200307 . PMID   17702723.
  23. ↑ Knight SR, Russell NK, Barcena L, Morris PJ (March 2009). "Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review". Transplantation. 87 (6): 785–94. doi: 10.1097/TP.0b013e3181952623 . PMID   19300178. S2CID   33596652.
  24. ↑ Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov BD, Ene-Iordache B, et al. (2004). "Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial". Lancet. 364 (9433): 503–12. doi:10.1016/S0140-6736(04)16808-6. PMID   15302193. S2CID   22033113.
  25. ↑ "CellCept, Myfortic (mycophenolate) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Archived from the original on 2021-04-30. Retrieved 2014-11-09.
  26. ↑ "Homepage - BNF Publications". www.bnf.org. Archived from the original on 2021-04-27. Retrieved 2014-11-09.
  27. ↑ "CellCept (mycophenolate mofetil) August 2009". U.S. Food and Drug Administration. August 14, 2009. Archived from the original on 2009-08-21. Retrieved 2009-08-21.
  28. ↑ "CellCept (mycophenolate mofetil) August 2009". U.S. Food and Drug Administration. August 14, 2009. Archived from the original on 2009-08-21. Retrieved 2009-08-21.
  29. ↑ "FDA Issues Second CellCept Warning". newsinferno.com. 2008-05-18. Archived from the original on 2013-02-24. Retrieved 2010-10-26.
  30. ↑ "MedWatch Safety Alerts for Human Medical Products". fda.gov. May 2008. Archived from the original on 2010-10-19. Retrieved 2010-10-26.
  31. ↑ Drugs.com: Mycophenolic acid Side Effects
  32. ↑ Pharmacology North American Edition. Lippincott Williams & Wilkins. 2014. p. 625. ISBN   978-1-4511-9177-6.
  33. ↑ Parnham FP, Nijkamp MJ, eds. (2005). Principles of immunopharmacology (2nd rev. and extended ed.). Basel: Birkhèauser Verlag. p.  453. ISBN   978-3764358044.
  34. ↑ Fu R, Ceballos-Picot I, Torres RJ, Larovere LE, Yamada Y, Nguyen KV, et al. (May 2014). "Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder". Brain. 137 (Pt 5): 1282–303. doi:10.1093/brain/awt202. PMC   3999711 . PMID   23975452.
  35. ↑ Anderson HA, Bracewell JM, Fraser AR, Jones D, Robertson GW, Russell JD (December 1988). "5-Hydroxymaltol and mycophenolic acid, secondary metabolites from Penicillium echinulatum". Transactions of the British Mycological Society. 91 (4): 649–651. doi:10.1016/S0007-1536(88)80040-8.
  36. ↑ Fulton B, Markham A (February 1996). "Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation". Drugs. 51 (2): 278–98. doi:10.2165/00003495-199651020-00007. PMID   8808168. S2CID   46954073.
  37. ↑ Ransom JT (December 1995). "Mechanism of action of mycophenolate mofetil". Therapeutic Drug Monitoring. 17 (6): 681–4. doi:10.1097/00007691-199512000-00023. PMID   8588241. S2CID   6439393.
  38. ↑ Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. (November 2011). "Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis". The New England Journal of Medicine. 365 (20): 1886–95. doi: 10.1056/NEJMoa1014460 . hdl: 20.500.12648/8250 . PMID   22087680. S2CID   27689350. Archived from the original on 2022-03-08. Retrieved 2021-11-25.
  39. ↑ Zhang W, Ding C, Zheng S (April 2014). "Enteric-coated mycophenolate sodium: an update". International Journal of Clinical Practice. Supplement. 68 (181): 1–3. doi: 10.1111/ijcp.12399 . PMID   24673712. S2CID   2630344.
  40. ↑ Lipsky JJ (November 1996). "Mycophenolate mofetil". Lancet. 348 (9038): 1357–9. doi:10.1016/S0140-6736(96)10310-X. PMID   8918281. S2CID   36837474.
  41. ↑ Zhang L, Demain AL (2005). Natural Products: Drug Discovery and Therapeutic Medicine. Totowa, N.J.: Humana Press. p. 14. ISBN   978-1-59259-976-9. Archived from the original on 2023-04-29. Retrieved 2019-08-16.
  42. ↑ Regueira TB, Kildegaard KR, Hansen BG, Mortensen UH, Hertweck C, Nielsen J (May 2011). "Molecular basis for mycophenolic acid biosynthesis in Penicillium brevicompactum". Applied and Environmental Microbiology. 77 (9): 3035–43. Bibcode:2011ApEnM..77.3035R. doi:10.1128/AEM.03015-10. PMC   3126426 . PMID   21398490.
  43. ↑ Bentley R (October 2000). "Mycophenolic Acid: a one hundred year odyssey from antibiotic to immunosuppressant". Chemical Reviews. 100 (10): 3801–26. doi:10.1021/cr990097b. PMID   11749328.
  44. ↑ Watts G (2014). "Anthony Clifford Allison". The Lancet. 383 (9925): 1290. doi: 10.1016/S0140-6736(14)60635-8 . S2CID   54281245.
  45. ↑ Allison AC (May 2000). "Immunosuppressive drugs: the first 50 years and a glance forward". Immunopharmacology. 47 (2–3): 63–83. doi:10.1016/S0162-3109(00)00186-7. PMID   10878284.
  46. ↑ Allison AC, Kowalski WJ, Muller CD, Eugui EM (November 1993). "Mechanisms of action of mycophenolic acid". Annals of the New York Academy of Sciences. 696 (1): 63–87. Bibcode:1993NYASA.696...63A. doi:10.1111/j.1749-6632.1993.tb17143.x. PMID   7906496. S2CID   34520788.
  47. ↑ Nelson PH, Eugui E, Wang CC, Allison AC (February 1990). "Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid". Journal of Medicinal Chemistry. 33 (2): 833–8. doi:10.1021/jm00164a057. PMID   1967654.
  48. ↑ Eugui EM, Allison AC (June 1993). "Immunosuppressive activity of mycophenolate mofetil". Annals of the New York Academy of Sciences. 685 (1): 309–29. Bibcode:1993NYASA.685..309E. doi:10.1111/j.1749-6632.1993.tb35881.x. PMID   8363235. S2CID   9028169.
  49. ↑ Allison AC, Eugui EM (February 1996). "Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)". Clinical Transplantation. 10 (1 Pt 2): 77–84. PMID   8680053.
  50. ↑ Allison AC, Eugui EM (1993). "The design and development of an immunosuppressive drug, mycophenolate mofetil". Springer Seminars in Immunopathology. 14 (4): 353–80. doi:10.1007/bf00192309. PMID   8322167. S2CID   26433174.
  51. ↑ Allison AC, Eugui EM (December 1993). "Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil". Immunological Reviews. 136 (1): 5–28. doi:10.1111/j.1600-065x.1993.tb00652.x. PMID   7907572. S2CID   711727.
  52. ↑ Bechstein WO, Suzuki Y, Kawamura T, Jaffee B, Allison A, Hullett DA, Sollinger HW (1992). "Low-dose combination therapy of DUP-785 and RS-61443 prolongs cardiac allograft survival in rats". Transplant International. 5 (Suppl 1): S482-3. doi:10.1111/tri.1992.5.s1.482. PMID   14621853. S2CID   222199749.
  53. ↑ Kawamura T, Hullett DA, Suzuki Y, Bechstein WO, Allison AM, Sollinger HW (April 1993). "Enhancement of allograft survival by combination RS-61443 and DUP-785 therapy". Transplantation. 55 (4): 691–4, discussion 694–5. doi: 10.1097/00007890-199304000-00001 . PMID   8475537.
  54. ↑ Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG (1994). "Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation". The Journal of Heart and Lung Transplantation. 13 (4): 571–82. PMID   7947873.
  55. ↑ "Risk Evaluation and Mitigation Strategy (REMS) Under Review for CellCept and Myfortic". U.S. Food and Drug Administration. Archived from the original on 8 August 2014. Retrieved 23 July 2014.
  56. ↑ Donlon DM (15 June 1995). "New Agent to Prevent Kidney Transplant Rejection Now Available". Stanford University. Archived from the original on 27 July 2014. Retrieved 23 July 2014.
  57. ↑ "CellCept registry data demonstrated superior long-term organ transplant outcomes". Roche.com. F. Hoffmann-La Roche Ltd. Archived from the original on 26 July 2014. Retrieved 23 July 2014.
  58. ↑ van Gelder T, Hesselink DA (May 2015). "Mycophenolate revisited". Transplant International. 28 (5): 508–15. doi: 10.1111/tri.12554 . PMID   25758949. S2CID   1673466.
  59. ↑ Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC (June 2003). "Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil". Archives of Dermatology. 139 (6): 739–42. doi: 10.1001/archderm.139.6.739 . PMID   12810504.
  60. ↑ Diamond MS, Zachariah M, Harris E (December 2002). "Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA". Virology. 304 (2): 211–21. doi: 10.1006/viro.2002.1685 . PMID   12504563.
  61. ↑ Takhampunya R, Ubol S, Houng HS, Cameron CE, Padmanabhan R (July 2006). "Inhibition of dengue virus replication by mycophenolic acid and ribavirin". The Journal of General Virology. 87 (Pt 7): 1947–52. doi: 10.1099/vir.0.81655-0 . PMID   16760396.
  62. ↑ Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. (December 2013). "Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus". The Journal of Infection. 67 (6): 606–16. doi: 10.1016/j.jinf.2013.09.029 . PMC   7112612 . PMID   24096239.
  63. ↑ Xiao Y, Huang J, Luo H, Wang J (February 2014). "Mycophenolate mofetil for relapsing-remitting multiple sclerosis". The Cochrane Database of Systematic Reviews. 2014 (2): CD010242. doi: 10.1002/14651858.CD010242.pub2 . PMC   10875409 . PMID   24505016.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.